Tarsus Pharmaceuticals Inc TARS

US Pharmaceuticals

$76.69 ▼ -0.16% ($-0.12)

Open $76.22

Prev Close $76.81

Day Range $75.53 – $77.99

52W Range $53.89 – $91.53

Market Cap $3.59B

Beta 0.34

EPS (TTM) $-1.08

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2020-10-16
Shares Out.	43,020,000
Website	tarsusrx.com/ ↗
Phone	13025310855
Employees	370
Revenue	$173.9M
Gross Profit	$161.8M
Net Income	-$18.6M
Free Cash Flow	$56.0M
Total Assets	$611.1M
Total Liabilities	$264.4M
Equity	$346.7M

About Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Tarsus Pharmaceuticals Inc is a publicly traded company under the ticker symbol TARS on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.